Epidarex Capital

All figures cover the European funds tracked here since 1 January 2025, whether closed or still raising, and are compiled from public sources.

Tracked funds

1

Reported volume

€125m

Latest public closing

29 Jan 2026

Reported volume sums the public fund amounts tracked here, not the manager's firm-wide assets under management, so it may differ from totals on the manager's website.

Early-stage life sciences venture capital firm building companies from UK and US research.

Focus: Early-stage life sciences and healthcare companies, including therapeutics and medical devices, built around breakthrough research in the UK and US

27 January 2026: Epidarex Capital IV announced a first close with more than $145m in commitments (company press release).